Drug nameFinasteride
DescriptionAn orally active testosterone 5-alpha-reductase inhibitor. It is used as a surgical alternative for treatment of benign prostatic hyperplasia. [PubChem]
DrugBankPrimary Accession Number: DB01216
DIN02238213
TypeApproved, Small Molecule
IndicationFor the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to: Improve symptoms, reduce the risk of acute urinary retention, reduce the risk of the need for surgery including transurethral resection of the prostate.
Mechanism of ActionThe mechanism of action of Finasteride is based on its preferential inhibition of Type II 5a-reductase, an intracellular enzyme that converts the androgen testosterone into DHT. Inhibition of Type II 5a-reductase blocks the peripheral conversion of testosterone to DHT, resulting in significant decreases in serum and tissue DHT concentrations.
AbsorptionNot available
ToxicityNot available
Protein BindingNot available
Interactions
RXListhttp://www.rxlist.com/cgi/generic3/propecia.htm
KEGGdrug: D00321 / compound: Not Available
PubChemcompound: 57363 / substance: 194453
PharmGKBNot available
Metabolizing Enzymes
NameGeneEntrezIDUniprotSNP
Cytochrome P450 2C19 (CYP2C19)CYP2C191557P33261rs58430367 rs17861152
Cytochrome P450 3A4 (CYP3A4)CYP3A41576P08684rs13306281
Target
NameGeneEntrezIDSwissprotSNP
Androgen receptorAR367ANDR_RABITrs55686369 rs35025615 rs9332972 rs9332971 rs9332970 rs9332969 rs9332968 rs5902610 rs3032358 rs1800053 rs6154 rs6153 rs6152
3-oxo-5-alpha-steroid 4-dehydrogenase 1SRD5A16715S5A1_HUMANrs3822430 rs248793 rs10062086 rs8192208 rs8192186 rs3736316 rs523854
FilesDB01216.mol | DB01216_2003-09-01.pdf | pdb_8072738125473-0.pdb | sdf_8514646414996-0.sdf |
Smilesisomeric:
CC(C)(C)NC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4NC(=O)C=C[C@]4(C)[C@H]3CC[C
@]12C
canonical:
CC(C)(C)NC(=O)C1CCC2C3CCC4NC(=O)C=CC4(C)C3CCC12C

© 2010-2020 All rights reserved. King Abdullah University of Science and Technology, All rights reserved